Fulton Breakefield Broenniman LLC Has $15.53 Million Stake in AbbVie Inc. $ABBV

Key Points

• Fulton Breakefield Broenniman LLC cut its AbbVie position by 25.7% in the second quarter, selling 21,305 shares and retaining 61,728 shares valued at $15.53 million. Institutional investors collectively own 70.23% of AbbVie.
• AbbVie exceeded quarterly expectations with EPS of $3.65 and revenue of $16.99 billion, up 10.2% year over year, and guided for third-quarter EPS of $3.84–$3.88. The company also declared a $1.73 quarterly dividend, equating to a 2.6% yield.
• Analysts maintain a “Moderate Buy” consensus with an average price target near $276, while AbbVie’s oncology and aesthetics pipeline offers potential growth. However, an early end to an emraclidine schizophrenia study and an $8.18 million executive share sale add uncertainty.

Fulton Breakefield Broenniman LLC decreased its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 25.7% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 61,728 shares of the company's stock after selling 21,305 shares during the period. AbbVie comprises 0.9% of Fulton Breakefield Broenniman LLC's portfolio, making the stock its 24th biggest position. Fulton Breakefield Broenniman LLC's holdings in AbbVie were worth $15,533,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of ABBV. ACT Advisors LLC. grew its holdings in AbbVie by 2.5% during the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company's stock worth $425,000 after purchasing an additional 41 shares during the period. Willner & Heller LLC raised its position in shares of AbbVie by 0.7% in the second quarter. Willner & Heller LLC now owns 5,852 shares of the company's stock valued at $1,472,000 after buying an additional 43 shares in the last quarter. B.O.S.S. Retirement Advisors LLC raised its position in shares of AbbVie by 3.1% in the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company's stock valued at $359,000 after buying an additional 43 shares in the last quarter. Leslie Global Wealth LLC lifted its position in shares of AbbVie by 1.5% during the 2nd quarter. Leslie Global Wealth LLC now owns 2,983 shares of the company's stock worth $751,000 after buying an additional 44 shares during the last quarter. Finally, Bank of Jackson Hole Trust increased its holdings in shares of AbbVie by 0.6% during the fourth quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company's stock worth $1,648,000 after buying an additional 44 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company's stock.

AbbVie Stock Performance

AbbVie stock opened at $265.62 on Friday. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47. The stock's 50 day moving average price is $248.48 and its two-hundred day moving average price is $227.49. The stock has a market capitalization of $469.29 billion, a price-to-earnings ratio of 75.03, a PEG ratio of 0.87 and a beta of 0.30.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. During the same period last year, the company posted $2.97 earnings per share. The business's quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts forecast that AbbVie Inc. will post 14.06 EPS for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie's dividend payout ratio is 195.48%.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New lung-cancer data supports AbbVie’s long-term growth strategy. At the 2026 World Conference on Lung Cancer, AbbVie presented clinical, translational and real-world data for investigational programs including ABBV-1480, telisotuzumab adizutecan and ABBV-706 across non-small cell and small cell lung cancer. The updates highlight potential future oncology revenue sources beyond the company’s established immunology portfolio. AbbVie WCLC 2026 announcement
• Positive Sentiment: AbbVie is broadening its aesthetics pipeline. The company has initiated a Phase 2 study evaluating a treatment for forehead lines, adding another potential product to its aesthetics franchise and reinforcing efforts to diversify growth. AbbVie aesthetics pipeline update
• Neutral Sentiment: AbbVie’s relatively low market correlation reflects its defensive pharmaceutical revenue base. Investor performance is driven more by product demand, reimbursement and payer dynamics than by broad equity-market movements. This may help explain the stock’s resilience, but the article does not identify a new earnings catalyst. What Moves AbbVie Stock
• Neutral Sentiment: AbbVie recently reported quarterly EPS and revenue above consensus, with revenue rising 10.2% year over year, and guided to third-quarter EPS of $3.84–$3.88. Analysts’ average price target of $275.73 remains above the current trading level, although the stock’s elevated valuation raises expectations. AbbVie stock and earnings information
• Negative Sentiment: An early end to a long-term emraclidine schizophrenia study introduces uncertainty. Investors may question the implications for AbbVie’s neuroscience pipeline and the program’s development prospects until the company provides additional details. AbbVie emraclidine study update
• Negative Sentiment: An executive vice president sold approximately $8.18 million of ABBV shares, reducing his position by about 30.5%. The sale may weigh modestly on sentiment, although insider transactions can reflect personal financial planning rather than a change in business outlook. AbbVie insider sale

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company's stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.06% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on ABBV shares. HSBC reiterated a "buy" rating and issued a $300.00 price objective on shares of AbbVie in a report on Monday, July 6th. Citigroup boosted their target price on shares of AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a report on Wednesday, July 15th. DZ Bank raised shares of AbbVie from a "hold" rating to a "strong-buy" rating in a research note on Thursday, April 30th. JPMorgan Chase & Co. increased their price target on AbbVie from $260.00 to $280.00 and gave the company an "overweight" rating in a research note on Thursday, July 9th. Finally, Wall Street Zen downgraded AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Sunday, July 5th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, AbbVie currently has an average rating of "Moderate Buy" and an average price target of $275.95.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source